15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
  • Patent number: 8933020
    Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 13, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Grzegorz Bulaj, H. Steve White
  • Publication number: 20150011477
    Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.
    Type: Application
    Filed: June 26, 2012
    Publication date: January 8, 2015
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
  • Publication number: 20150011466
    Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.
    Type: Application
    Filed: January 9, 2013
    Publication date: January 8, 2015
    Inventors: Thomas J. McMurry, Richard J. Looby
  • Publication number: 20150011471
    Abstract: The present invention provides compositions for use in the treatment of long-established type 1 diabetes (T1D) using peptides and analogs of heat shock protein 60 (Hsp60). The invention is exemplified using DiaPep277, a peptide analog of human Hsp60, which is shown to induce increase in plasma C-peptide and regeneration of islet beta cells. The invention further relates to regimens useful for treatment of long established T1D in patients having no demonstrable islet beta cell-function.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 8, 2015
    Inventors: Irun R. Cohen, Raanan Margalit
  • Publication number: 20150011729
    Abstract: Isolated polypeptides that are endogenously expressed from nucleotide repeat expansions are disclosed. In some cases, the polypeptides include polypeptide repeats. In some cases, the polypeptide repeats include at least five contiguous repeats of a single amino acid. In other cases, the repeats include at least six contiguous amino acids of a tetra- or penta-amino acid repeat block.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 8, 2015
    Inventors: Laura P.W. Ranum, Tao Zu
  • Patent number: 8926946
    Abstract: A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes a targeting moiety of one of peptides ?3, 2?3, 3?3, A1, B7, B8, B9, B1O, and D6, specific for targeting ICAM-I. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 6, 2015
    Assignee: University of Maryland, College Park
    Inventors: Silvia Muro Galindo, Ming Meng, Carmen Garnacho Montero
  • Patent number: 8927500
    Abstract: Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: January 6, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Vincent Guerlavais, Carl Elkin, Huw M. Nash, Tomi K. Sawyer, Bradford J. Graves, Eric Feyfant
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Patent number: 8927489
    Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: January 6, 2015
    Assignee: Cebix Incorporated
    Inventors: John Wahren, Anders Carlsson
  • Publication number: 20150004189
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 1, 2015
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Publication number: 20150004185
    Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.
    Type: Application
    Filed: April 29, 2014
    Publication date: January 1, 2015
    Applicant: University of Saskatchewan
    Inventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
  • Publication number: 20150005237
    Abstract: The present invention relates to novel peptidic inhibitors of signal transmission from G?s- to G?i-coupled receptor cascades and methods for their use.
    Type: Application
    Filed: December 5, 2012
    Publication date: January 1, 2015
    Applicants: UNIVERSITÄT INNSBRUCK, UNIVERSITÄT INNSBRUCK
    Inventors: Eduard Stefan, Verena Bachmann, Roland Huber
  • Publication number: 20150004157
    Abstract: The present invention relates to a therapeutic comprising an osteopontin isoform a (“OPNa”) inhibitor where the OPNa inhibitor blocks activity of extracellular OPNa exon 4. The OPNa inhibitor is selected from the group consisting of (i) an exon-4 specific antibody or binding portion thereof; (ii) a peptide mimic of OPNa exon 4 or a fragment thereof; (iii) a nucleic acid aptamer that specifically binds to OPNa exon 4 or a fragment thereof; and (iv) a peptide inhibitor that binds to OPNa exon 4 or a fragment thereof. The present invention also relates to methods of inhibiting tumor growth and/or metastasis in a subject, treating a subject with chemotherapeutic resistance, and methods of increasing tumor cell sensitivity to a cancer therapeutic by administering an OPNa inhibitor according to the present invention.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 1, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Harvey I. Pass, Jessica S. Donington, Chandra M. Goparaju
  • Patent number: 8921306
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The University of Queensland
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • Patent number: 8921106
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: December 30, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
  • Patent number: 8921323
    Abstract: The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: December 30, 2014
    Assignees: Dana Farber Cancer Institute, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Loren D. Walensky, Nico Tjandra, Evripidis Gavathiotis, Motoshi Suzuki, Gregory Bird
  • Patent number: 8921517
    Abstract: The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-(D)-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH (SEQ ID NO: 1).
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: December 30, 2014
    Assignee: Lonza Braine SA
    Inventors: Geoffroy Sommen, Luciano Forni
  • Publication number: 20140378378
    Abstract: Provided are a peptide, which has an amino acid sequence of SEQ ID NO. 1 and is effective for the prevention of cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active component. The peptide according to the present invention not only exhibits substantially better biological activities than conventional natural human erythropoietin in terms of various cell protection activities, but also has a substantially simpler structure than the natural human erythropoietin. Thus, the peptide may easily pass through a tissue-blood barrier and is economically advantageous due to its low production cost.
    Type: Application
    Filed: September 29, 2012
    Publication date: December 25, 2014
    Inventor: Hoojung Kim
  • Publication number: 20140378387
    Abstract: Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTa1-3-2 (Y142-K172) amino acid sequence as shown by SEQ ID NO:1 or SEQ ID NO:5 to a subject in need of the treatment.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 25, 2014
    Applicant: CENTRE FOR ADDICTION AND MENTAL HEALTH
    Inventor: Fang Liu
  • Publication number: 20140378372
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 7, 2013
    Publication date: December 25, 2014
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20140378384
    Abstract: A series of polypeptides presenting high integrin affinity and bonding capacity is provided. Three polypeptides among said series can be adopted in prevention and treatment of rheumatoid arthritis. Said three polypeptides are: polypeptide I: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro (SEQ ID NO. 1) (two pairs of disulfide bonds contained in the sequence are pairing in the pattern of 1-4 and 2-3); Polypeptide II: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO. 2); and polypeptide III: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO. 3). These polypeptides can be adopted in treatment of rheumatoid arthritis.
    Type: Application
    Filed: December 25, 2012
    Publication date: December 25, 2014
    Inventor: HANMEI XU
  • Publication number: 20140377289
    Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
  • Publication number: 20140377542
    Abstract: A plate with titanium dioxide on its surface, as well as its manufacturing process and uses thereof are provided. The plate comprises (A) a substrate; (B) a polydimethylsiloxane (PDMS) layer on at least one surface of the substrate; and (C) one or more aggregations of titanium dioxide particles on the polydimethylsiloxane layer. The plate is useful in the purification of phosphopeptides.
    Type: Application
    Filed: September 12, 2013
    Publication date: December 25, 2014
    Inventors: Chao-Jung Chen, Yu-Ching Liu
  • Publication number: 20140371154
    Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 18, 2014
    Applicant: Trustees of Tufts College
    Inventor: Ira M. Herman
  • Publication number: 20140371155
    Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 18, 2014
    Applicant: Trustees of Tufts College
    Inventor: Ira M. Herman
  • Publication number: 20140371152
    Abstract: A primary object of the present invention is to develop a compound that specifically inhibits the production of A? protein and serves as an active ingredient of a drug to treat and/or prevent Alzheimer's disease. This object can be achieved by a polypeptide having the amino acid sequence represented by any one of SEQ ID NOs: 1, 13, 14, and 22, that binds to the N-terminal region of ?CTF; a ?-secretase activity inhibitor containing the polypeptide; ?-secretase activity inhibitor; A? protein production inhibitor; and an agent for treating and/or preventing Alzheimer's disease.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 18, 2014
    Applicant: THE DOSHISHA
    Inventors: Yasuo Ihara, Satoru Funamoto, Toru Sasaki
  • Patent number: 8912148
    Abstract: The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 16, 2014
    Assignee: Covx Technology Ireland, Ltd.
    Inventors: Curt Bradshaw, Abhijit Bhat, Jing Yu Lai, Venkata Doppalapudi, Dingguo Liu
  • Patent number: 8911953
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: December 16, 2014
    Assignee: Thrasos Innovation, Inc.
    Inventors: William D. Carlson, Peter C. Keck, Dattatreyamurty Bosukonda, Philippe Bey
  • Publication number: 20140363462
    Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.
    Type: Application
    Filed: July 31, 2014
    Publication date: December 11, 2014
    Inventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
  • Publication number: 20140364368
    Abstract: The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Inventors: Kevin Yu-ming Lin, Sangeeta N. Bhatia, Gabriel Abner Kwong, Justin Han-je Lo
  • Patent number: 8906844
    Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: December 9, 2014
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell
  • Patent number: 8906865
    Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: December 9, 2014
    Assignee: ISIS Innovation Limited
    Inventors: David R. Greaves, Andreas Russ, Jenna L. Cash
  • Patent number: 8906845
    Abstract: The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: December 9, 2014
    Assignee: Eastern Virginia Medical School
    Inventors: Neel K. Krishna, Kenji M. Cunnion
  • Patent number: 8907055
    Abstract: There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: December 9, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Prasanna R. Kolatkar, Irene Aksoy, Ralf Jauch, Lawrence W. Stanton
  • Patent number: 8907054
    Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: December 9, 2014
    Assignee: Marquette University
    Inventors: Pinfen Yang, Priyanka Sivadas
  • Publication number: 20140356409
    Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 4, 2014
    Inventor: Patrick M. Schlievert
  • Publication number: 20140357520
    Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.
    Type: Application
    Filed: February 7, 2013
    Publication date: December 4, 2014
    Inventor: Kimberly Luke
  • Publication number: 20140356418
    Abstract: Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding sequence may be retroinverted D-peptide mimetic of an L-peptide binding sequence and the transit sequence may be a D-peptide mimetic of an L-peptide transit sequence (e.g. TAT) The preferred peptide construct comprises the sequence rGffvlkGrrrrqrrkkrGy. The preferred carrier particles are liposomes.
    Type: Application
    Filed: October 10, 2012
    Publication date: December 4, 2014
    Inventors: Mark Neville Taylor, David Allsop
  • Publication number: 20140356284
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.
    Type: Application
    Filed: February 10, 2012
    Publication date: December 4, 2014
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis
  • Publication number: 20140357512
    Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Applicant: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Min Yang, Simon S. Jones
  • Publication number: 20140356320
    Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
    Type: Application
    Filed: July 23, 2012
    Publication date: December 4, 2014
    Applicant: Universität Zürich
    Inventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
  • Patent number: 8900880
    Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 2, 2014
    Assignee: Toscana Biomarkers S.R.L.
    Inventors: Paola Migliorini, Federico Pratesi
  • Publication number: 20140348861
    Abstract: Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or ?3-homo amino acid.
    Type: Application
    Filed: May 3, 2012
    Publication date: November 27, 2014
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Avadhesha Surolia, Ravi Kant Gautam, Vishnu Kumar Dwivedi, Sarika Gupta
  • Publication number: 20140349917
    Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 27, 2014
    Applicant: C3 JIAN, INC.
    Inventors: RANDAL H. ECKERT, CHRIS KAPLAN, JIAN HE, DANIEL K. YARBROUGH, MAXWELL ANDERSON, JEE-HYUN SIM
  • Publication number: 20140350218
    Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
    Type: Application
    Filed: April 15, 2014
    Publication date: November 27, 2014
    Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: MAREN WATKINS, BALDOMERO M. OLIVERA, DAVID R. HILLYARD, J. MICHAEL MCINTOSH
  • Publication number: 20140348902
    Abstract: Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided.
    Type: Application
    Filed: November 19, 2012
    Publication date: November 27, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sattva S. Neelapu, Jinsheng Weng
  • Publication number: 20140349945
    Abstract: A PEG-oligopeptide-irinotecan conjugate has the general formula (I) (shown below) and a pharmaceutical composition containing the conjugate are disclosed. In the conjugate, PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons; (AA)i represents an oligopeptide, AA represents the same or different amino acids in the oligopeptide; i is an integer of 2-12 representing the number of amino acids in the oligopeptide; j is an integer of 2-12 representing the number of irinotecan connected with the oligopeptide. In the conjugate, each terminal group of PEG can link with multiple irinotecans through oligopeptides, thereby greatly increasing the drug-loading capacity. Modification of the hydrophilic polymer can provide protection for the irinotecan, thereby improving drug absorption, prolonging the action time, enhancing the efficacy, reducing the dose and avoiding the toxic and side-effects.
    Type: Application
    Filed: November 7, 2012
    Publication date: November 27, 2014
    Applicants: JENKEM TECHNOLOGYCO., LTD.. (TIANJIN), JENKEM TECHNOLOGY CO., LTD(BEIJING)
    Inventors: Lihua Xu, Wenzhe Huang, Xuan Zhao
  • Publication number: 20140349920
    Abstract: N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 27, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Patent number: 8895697
    Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: November 25, 2014
    Assignee: Natimab Therapeutics S.r.l.
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Patent number: 8895514
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 25, 2014
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh